Alosetron
A selective serotonin 5-HT3 receptor antagonist that reduces the hypersensitivity and abnormal gut contractions characteristic of severe diarrhea-predominant irritable bowel syndrome (IBS-D) in women. By blocking these receptors in the gut, it slows intestinal transit, reduces urgency, and decreases pain.
Peso molecular
294,3500 g/mol
LogP
1,60
TPSA
53,90 Ų
Regla de cinco de Lipinski
Cumple
Mecanismo de acción
Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.
Estructura 2D
Cite this structure
Embed this structure
SMILES
Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
InChI
InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19)
Molecular Formula
C17H18N4O
HBD / HBA
1 / 2
Enlaces Rotables
2
Átomos Pesados
22
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A selective serotonin 5-HT3 receptor antagonist that reduces the hypersensitivity and abnormal gut contractions characteristic of severe diarrhea-predominant irritable bowel syndrome (IBS-D) in women. By blocking these receptors in the gut, it slows intestinal transit, reduces urgency, and decreases pain.
Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.
Yes, Alosetron is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1110. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2099. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="alosetron"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/alosetron/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/alosetron/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/alosetron/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="alosetron"></drugfyi-drug>